Kimio Yonesaka Selected Research

Disease Progression

9/2021	CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
4/2016	Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
11/2010	Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
11/2008	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kimio Yonesaka Research Topics

Disease

30	Neoplasms (Cancer) 01/2023 - 02/2006
26	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 11/2008
11	Colorectal Neoplasms (Colorectal Cancer) 03/2021 - 06/2011
7	Lung Neoplasms (Lung Cancer) 01/2023 - 02/2006
4	Disease Progression 09/2021 - 11/2008
4	Stomach Neoplasms (Stomach Cancer) 01/2018 - 12/2016
3	Squamous Cell Carcinoma of Head and Neck 03/2021 - 11/2008
2	Esophageal Squamous Cell Carcinoma 04/2023 - 01/2023
2	Adenocarcinoma of Lung 01/2023 - 11/2013
2	Melanoma (Melanoma, Malignant) 01/2021 - 03/2018
2	Breast Neoplasms (Breast Cancer) 01/2019 - 12/2016
1	Adenocarcinoma 01/2023
1	Pneumonia (Pneumonitis) 01/2022
1	Fibrosis (Cirrhosis) 01/2021
1	Hepatitis 01/2020
1	Dyspnea (Shortness of Breath) 05/2016
1	Fistula 05/2016
1	Pneumothorax 05/2016
1	Infections 12/2014
1	Exanthema (Rash) 03/2014
1	Liver Diseases (Liver Disease) 03/2014
1	Deglutition Disorders (Dysphagia) 03/2014
1	Keratitis 08/2011

Drug/Important Bio-Agent (IBA)

16	ErbB Receptors (EGF Receptor)IBA 01/2023 - 11/2008
11	Tyrosine Kinase InhibitorsIBA 01/2023 - 11/2008
10	LigandsIBA 01/2021 - 11/2008
10	Neuregulin-1 (Neuregulin 1)IBA 12/2019 - 09/2011
10	Cetuximab (Erbitux)FDA Link 09/2019 - 11/2008
5	Immune Checkpoint InhibitorsIBA 01/2023 - 03/2018
5	AfatinibIBA 01/2023 - 10/2015
5	patritumabIBA 01/2019 - 12/2014
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 11/2008
4	osimertinibIBA 01/2023 - 02/2019
4	Biomarkers (Surrogate Marker)IBA 01/2018 - 12/2016
3	Fluorouracil (Carac)FDA LinkGeneric 04/2023 - 12/2016
3	NivolumabIBA 01/2023 - 01/2018
3	patritumab deruxtecanIBA 01/2022 - 01/2020
3	Circulating Tumor DNAIBA 09/2021 - 01/2016
3	Bevacizumab (Avastin)FDA Link 10/2020 - 04/2016
3	Messenger RNA (mRNA)IBA 10/2019 - 12/2016
3	Trastuzumab (Herceptin)FDA Link 01/2019 - 12/2016
3	Epidermal Growth Factor (EGF)IBA 01/2017 - 11/2008
3	AmphiregulinIBA 03/2015 - 11/2008
3	Gefitinib (Iressa)FDA Link 09/2014 - 11/2008
2	Cisplatin (Platino)FDA LinkGeneric 04/2023 - 01/2023
2	Docetaxel (Taxotere)FDA Link 04/2023 - 01/2023
2	human ERBB2 proteinIBA 01/2023 - 12/2019
2	Immunoconjugates (Immunoconjugate)IBA 03/2021 - 10/2017
2	ParaffinIBA 01/2021 - 01/2019
2	Formaldehyde (Formol)FDA Link 01/2021 - 01/2019
2	Panitumumab (Vectibix)FDA Link 10/2020 - 12/2016
2	trastuzumab deruxtecanIBA 12/2019 - 10/2017
2	Phosphotransferases (Kinase)IBA 01/2017 - 11/2013
2	histidine-rich proteinsIBA 01/2017 - 12/2014
2	Monoclonal AntibodiesIBA 01/2017 - 11/2013
2	SurvivinIBA 04/2007 - 02/2006
1	atezolizumabIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2022
1	sotorasibIBA 10/2021
1	nintedanibIBA 01/2021
1	Vascular Endothelial Growth Factor DIBA 10/2020
1	AlarminsIBA 01/2020
1	exatecan (DX 8951f)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 12/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2019
1	pertuzumabIBA 01/2019
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2019
1	Immune Checkpoint ProteinsIBA 01/2018
1	S-1 plus cisplatinIBA 01/2018
1	Indicators and Reagents (Reagents)IBA 12/2017
1	Dasatinib (BMS 354825)FDA Link 11/2017
1	Topoisomerase I InhibitorsIBA 10/2017
1	Ado-Trastuzumab EmtansineIBA 12/2016
1	Lapatinib (GW572016)FDA Link 12/2016
1	Leucovorin (Folinic Acid)FDA Link 12/2016
1	Blood Proteins (Serum Proteins)IBA 12/2016
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2016
1	PlatinumIBA 04/2016
1	seribantumabIBA 01/2016
1	elgemtumabIBA 01/2016
1	EGF Family of ProteinsIBA 03/2015
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2015
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 03/2015
1	Ophthalmic Solutions (Eye Drops)IBA 08/2011
1	Dexamethasone (Maxidex)FDA LinkGeneric 06/2011
1	Platinum Compounds (Compounds, Platinum)IBA 06/2011
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2011

Therapy/Procedure

23	Therapeutics 01/2023 - 11/2008
5	Drug Therapy (Chemotherapy) 01/2023 - 04/2016
3	Immunotherapy 01/2020 - 01/2018
2	Neoadjuvant Therapy 04/2023 - 01/2023
2	Combination Drug Therapy (Combination Chemotherapy) 01/2023 - 01/2021
2	Aftercare (After-Treatment) 10/2019 - 04/2016
2	Radiotherapy 05/2016 - 06/2013
1	Precision Medicine 01/2021
1	Plasma Exchange 01/2020
1	Re-Irradiation 05/2016
1	Gastrostomy 03/2014
1	Duration of Therapy 06/2011
1	Premedication 06/2011